中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

286 records (took 0.052 seconds)

    Therapeutic use of specific ligand in MSRV associated diseases
    121.
    发明授权
    Therapeutic use of specific ligand in MSRV associated diseases 有权
    特异性配体在MSRV相关疾病中的治疗用途

    公开(公告)号：US08715656B2

    公开(公告)日：2014-05-06

    申请号：US12997486

    申请日：2009-07-08

    Applicant: Corinne Bernard ,  Alois Bernhardt Lang ,  Herve Perron ,  Jean-Baptiste Bertrand

    Inventor： Corinne Bernard ,  Alois Bernhardt Lang ,  Herve Perron ,  Jean-Baptiste Bertrand

    IPC: A61K39/395

    CPC classification number: C07K16/1036 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92

    Abstract: The present invention deals with a ligand comprising each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1(SEQ ID No. 1), from 0 to 2 in CDR2(SEQ ID No. 2), from 0 to 2 in CDR3(SEQ ID No. 3), from 0 to 1 in CDR4(SEQ ID No. 4), from 0 to 4 in CDR5(SEQ ID No. 5), from 0 to 2 in CDR6(SEQ ID No. 6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.

    Abstract translation: 本发明涉及包含SEQ ID No.1，SEQ ID No.2，SEQ ID No.3，SEQ ID No.4，SEQ ID No.5所示的每个互补决定区（CDR）和 SEQ ID No.6或在所述序列中具有任意数目的取代氨基酸的序列，如下所示，CDR1（SEQ ID No.1）中为0至3，CDR2（SEQ ID No.2）为0至2， 在CDR3（SEQ ID No.3）中为0至2，CDR4（SEQ ID No.4）为0至1，CDR5（SEQ ID No.5）为0至4，CDR6（SEQ ID NO：0）为0至2 SEQ ID NO：6），或在所述序列SEQ ID No.1至SEQ ID No.6内具有等同化学功能和性质的其它氨基酸取代的氨基酸。

    Gammaretrovirus associated with cancer
    124.
    发明授权
    Gammaretrovirus associated with cancer 失效
    与癌症相关的瘤胃病毒

    公开(公告)号：US08263085B2

    公开(公告)日：2012-09-11

    申请号：US11903756

    申请日：2007-09-24

    Applicant: Robert H. Silverman ,  Eric A. Klein ,  Graham Casey ,  Joseph DeRisi ,  Don Ganem

    Inventor： Robert H. Silverman ,  Eric A. Klein ,  Graham Casey ,  Joseph DeRisi ,  Don Ganem

    IPC: A61K39/21 ,  C12N5/071 ,  C12N7/00

    CPC classification number: C12N7/00 ,  A61K39/00 ,  C07K14/005 ,  C07K16/1036 ,  C12N9/22 ,  C12N2740/13021 ,  C12N2740/13022 ,  C12Q1/6886 ,  C12Q1/70 ,  C12Q1/701 ,  C12Q2600/136

    Abstract: The present invention provides for isolated nucleic acid sequences encoding viruses; isolated polypeptides comprising amino acid sequences of the virus; vectors comprising the viral nucleic acid sequences; cells comprising the vectors; antibodies and antigen binding fragments thereof which have binding specificity for the virus; methods of detecting or screening for the virus (e.g., in an individual); methods of identifying agents that inhibit the virus; methods of inducing an immune response to the virus; methods of treating disease associated with the presence of XMRV in an individual (e.g., cancer such as prostate cancer); methods of detecting asymptomatic cancer (e.g., prostate cancer); methods of identifying an individual at risk for developing cancer (e.g., prostate cancer); and kits for detecting the virus.

    Abstract translation: 本发明提供了编码病毒的分离的核酸序列; 包含病毒的氨基酸序列的分离的多肽; 包含病毒核酸序列的载体; 包含载体的细胞; 对病毒具有结合特异性的抗体及其抗原结合片段; 检测或筛选病毒的方法（例如，在个体中）; 识别抑制病毒的药剂的方法; 诱导对病毒的免疫应答的方法; 治疗与个体（例如癌症如前列腺癌）中XMRV存在相关的疾病的方法; 检测无症状癌症的方法（例如前列腺癌）; 识别患有癌症风险的个体（例如前列腺癌）的方法; 和用于检测病毒的工具包。

    Versatile reagent for detecting murine leukemia viruses
    129.
    发明授权
    Versatile reagent for detecting murine leukemia viruses 失效
    用于检测鼠白血病病毒的通用试剂

    公开(公告)号：US06709811B1

    公开(公告)日：2004-03-23

    申请号：US08046352

    申请日：1993-04-08

    Applicant: Leonard H Evans ,  William J Britt

    Inventor： Leonard H Evans ,  William J Britt

    IPC: C12Q170

    CPC classification number: C07K16/1036 ,  G01N33/56983 ,  G01N2333/15

    Abstract: A method for detecting broad spectrum of murine leukemia viruses belonging to any or all of the ecotropic, xenotropic, polytropic and amphotropic groups, has been described. The method utilizes a monoclonal antibody designated 83A25 which identifies almost all classes or groups of the murine leukemia virus with only a few exceptions.

    Abstract translation: 已经描述了用于检测属于任何或全部的嗜酸性，异位性，多嗜性和独立性基团的广泛的小鼠白血病病毒的方法。 该方法使用指定为83A25的单克隆抗体，其仅识别几乎所有类别或组的小鼠白血病病毒，仅有少数例外。

    Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses
    130.
    发明申请
    Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses 失效
    使用已经失活的免疫原性免疫抑制和/或血管生成蛋白，其制备方法和药物或疫苗用途

    公开(公告)号：US20040001852A1

    公开(公告)日：2004-01-01

    申请号：US10465645

    申请日：2003-06-20

    Applicant: NEOVACS 11, RUE PERNETY

    Inventor： Daniel A. Zagury ,  Jean-Francois Zagury

    IPC: A61K039/21 ,  C07K014/16

    CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  C07K16/084 ,  C07K16/1036 ,  C07K16/1072 ,  C07K2319/21 ,  C07K2319/55 ,  C12N2710/20022 ,  C12N2740/14022 ,  C12N2740/16322

    Abstract: The invention concerns the use of a protein derived from cancer cells, virus-infected cells or immune-defence cells or a fragment of said protein, characterized in that said protein is initially an immunosuppressive and/or angiogenic protein with local activity and said properties are inactivated by at least 70%, through a physical and/or chemical treatment, by genetic recombination or by adjuvant conditioning, said treatment preserving its property of being identified by antibodies directed afainst said protein, and preserving sufficient immunogenic properties for generating antibodies neutralizing or blocking said native protein, to obtain a medicine for use as local anti-immnumosuppression and/or anti-angiogenic agent as an anticancer agent. The invention also concerns the resulting immunogenic compounds, their preparation method and their uses.

    Abstract translation: 本发明涉及使用衍生自癌细胞，病毒感染细胞或免疫防御细胞或所述蛋白质片段的蛋白质，其特征在于所述蛋白质最初是具有局部活性的免疫抑制和/或血管生成蛋白质，并且所述性质是 通过物理和/或化学处理，通过遗传重组或辅助调理灭活至少70％，所述处理保持其被定位在所述蛋白质上的抗体鉴定的性质，并保留足够的免疫原性以产生中和或阻断的抗体 所述天然蛋白质，以获得用作局部抗免疫抑制和/或抗血管生成剂作为抗癌剂的药物。 本发明还涉及所得的免疫原性化合物，其制备方法及其用途。

Patent Agency Ranking